The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.
about
Meningococcal B Vaccination (4CMenB) in Infants and ToddlersProtein Crystallography in Vaccine Research and DevelopmentEmerging experience with meningococcal serogroup B protein vaccines.Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).Meningococcal Serogroup B Bivalent rLP2086 Vaccine Elicits Broad and Robust Serum Bactericidal Responses in Healthy Adolescents.Optimization of Molecular Approaches to Genogroup Neisseria meningitidis Carriage Isolates and Implications for Monitoring the Impact of New Serogroup B VaccinesCan immunological principles and cross-disciplinary science illuminate the path to vaccines for HIV and other global health challenges?Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccineMeningococcal serogroup B vaccines: Estimating breadth of coverage.Neisseria meningitidis factor H-binding protein fHbp: a key virulence factor and vaccine antigen.Immunogenicity, Safety, and Tolerability of Bivalent rLP2086 Meningococcal Group B Vaccine Administered Concomitantly With Diphtheria, Tetanus, and Acellular Pertussis and Inactivated Poliomyelitis Vaccines to Healthy Adolescents.Bivalent rLP2086 Vaccine (Trumenba(®)): A Review in Active Immunization Against Invasive Meningococcal Group B Disease in Individuals Aged 10-25 Years.The next chapter for group B meningococcal vaccines.Liposomes or traditional adjuvants: induction of bactericidal activity by the macrophage infectivity potentiator protein (Mip) of Neisseria meningitidis.The role of structural proteomics in vaccine development: recent advances and future prospects.Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix™): A review of its immunogenicity, safety, co-administration, and antibody persistence.Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.Distinct evolutionary patterns of Neisseria meningitidis serogroup B disease outbreaks at two universities in the USA.Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine.
P2860
Q26782285-DD8713B6-9910-4353-9DA8-EC62F91743C6Q28087528-A30F0B5A-A422-41E1-A8AC-B9484D137D6CQ30234958-BE11D7C9-7FBC-41C8-A961-11767E69F4ABQ30248749-9C2921E5-5391-4E13-B192-DCED04D5C3CEQ33609246-21400B80-E169-4A43-ADFC-52CE29F16DF5Q35683382-199F12A8-A539-4F29-B6AE-EE7A08A567FBQ35923859-FE1613A2-96FD-4BFD-B325-C66BF127D167Q36434366-487DB6D7-E935-4A66-BD6F-F60A5ABAD1B3Q36521563-6346311B-48B2-4956-8976-AC4CA7445A65Q37669413-3719DB9B-D618-40D3-90A3-80E9F7BC7024Q38363907-0F51D849-EA0C-48A4-A09A-84EF937AE938Q38396843-FB5D75D9-A3EA-422A-B786-1C42E91E62C9Q38591053-654CFF9C-166E-47C3-8547-07A06748764CQ38677309-62121D79-1F9F-4EA4-99E5-558C9DA6599FQ38679116-3FAD39F4-22C4-4C2B-8B05-2A67DB63AA83Q38682335-B5F7EA04-632B-4792-91B2-D9543D1D33F2Q38743826-62AAD6E5-8527-4EE0-8EFF-F90D51C8FAF2Q40172533-1A487F2F-36BF-4E37-B834-E60047DEF310Q40178578-5EC69EA5-8CE6-45A4-AD90-2CBC10D99FEBQ52332492-650D90E6-4273-4174-BAA0-4AE609EDB4BDQ52657380-071493D8-D353-4848-AA56-93B47E3BAEF4
P2860
The discovery and development of a novel vaccine to protect against Neisseria meningitidis Serogroup B Disease.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The discovery and development ...... ingitidis Serogroup B Disease.
@ast
The discovery and development ...... ingitidis Serogroup B Disease.
@en
type
label
The discovery and development ...... ingitidis Serogroup B Disease.
@ast
The discovery and development ...... ingitidis Serogroup B Disease.
@en
prefLabel
The discovery and development ...... ingitidis Serogroup B Disease.
@ast
The discovery and development ...... ingitidis Serogroup B Disease.
@en
P2093
P2860
P356
P1476
The discovery and development ...... ingitidis Serogroup B Disease.
@en
P2093
Annaliesa S Anderson
Duzhang Zhu
Gary W Zlotnick
John Perez
Joseph Eiden
Kathrin U Jansen
Lisa K McNeil
Paul Liberator
Shannon Harris
P2860
P356
10.4161/HV.34293
P577
2014-11-01T00:00:00Z